Targeted Therapy for Cancer — Cost, Top Hospitals & Success Rates | MyMedicPlus

Targeted therapy refers to cancer treatments that specifically target molecular alterations — mutations, amplifications, fusions, or overexpression of specific proteins — that drive cancer cell growth and survival. Unlike conventional chemotherapy, which non-selectively kills rapidly dividing cells, targeted therapies are designed to disrupt specific oncogenic pathways with greater precision, achieving higher efficacy in biomarker-selected patients with more manageable toxicity profiles.

The era of molecular targeted oncology began in 2001 with the approval of imatinib (Gleevec, Novartis) for BCR-ABL+ chronic myeloid leukaemia — a drug so effective it converted a uniformly fatal disease into a manageable chronic condition. This paradigm — identifying a specific oncogenic driver, developing a drug to target it, and selecting patients based on tumour molecular profiling — has since produced transformative targeted therapies across virtually every cancer type.

The broad categories of targeted therapy include: small molecule tyrosine kinase inhibitors (TKIs) — oral agents that penetrate cells and block oncogenic signalling kinases (EGFR, ALK, BCR-ABL, BRAF, KRAS G12C, CDK4/6, PARP); monoclonal antibodies — IV-administered antibodies targeting cell surface receptors (trastuzumab for HER2, cetuximab for EGFR, bevacizumab for VEGF); antibody-drug conjugates (ADCs) — antibodies conjugated to cytotoxic payloads, delivering intracellular chemotherapy to targeted cells (trastuzumab deruxtecan, sacituzumab govitecan); and bispecific antibodies — engaging T-cells against tumour-specific antigens (blinatumomab, amivantamab). Next-generation sequencing (NGS) of tumour DNA has made comprehensive molecular profiling standard practice in oncology, unlocking actionable targets in an ever-growing proportion of cancer patients.

• Non-small cell lung cancer (NSCLC): The richest landscape of targetable mutations in oncology. EGFR mutation (~15% Western, 40–50% Asian): osimertinib (3rd gen), gefitinib, erlotinib. ALK rearrangement (~5%): alectinib, brigatinib, lorlatinib. ROS1 rearrangement (~1–2%): entrectinib, crizotinib. BRAF V600E (~2–3%): dabrafenib + trametinib. KRAS G12C (~13%): sotorasib, adagrasib. MET exon 14 skipping (~3–4%): tepotinib, capmatinib. RET rearrangement (~1–2%): selpercatinib, pralsetinib. NTRK fusion: larotrectinib, entrectinib. HER2 mutation: trastuzumab deruxtecan.
• Breast cancer: HER2+ disease: trastuzumab + pertuzumab + taxane (first-line metastatic; perioperative for early); T-DM1 (ado-trastuzumab emtansine) for HER2+ after trastuzumab; trastuzumab deruxtecan (T-DXd) for HER2+ post-T-DM1 (DESTINY-Breast03 — superior to T-DM1). HR+ disease: CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) + aromatase inhibitor; abemaciclib adjuvant for high-risk early BC (monarchE). BRCA1/2-mutated metastatic BC: olaparib, talazoparib. PI3K-mutated HR+ disease: alpelisib + fulvestrant. TROP2: sacituzumab govitecan for TNBC and HR+/HER2- post-endocrine therapy.
• Colorectal cancer: KRAS/NRAS/BRAF wild-type mCRC: cetuximab or panitumumab (EGFR antibodies) + chemotherapy. BRAF V600E-mutated mCRC: encorafenib + cetuximab (BEACON trial: ORR 26%, mOS 8.4 months vs. 5.4 months with standard therapy). HER2-amplified mCRC: trastuzumab + pertuzumab (HERACLES trial). VEGF: bevacizumab + FOLFOX or FOLFIRI.
• CML and GIST: Imatinib (1st-gen TKI) cures/controls >90% of chronic phase CML; later generations (dasatinib, nilotinib, ponatinib) for resistance. KIT/PDGFRA-mutated GIST: imatinib first-line; sunitinib, regorafenib, ripretinib for subsequent lines.
• Thyroid cancer: RET-altered thyroid cancer (medullary and papillary): selpercatinib, pralsetinib. BRAF V600E papillary thyroid cancer: vemurafenib, dabrafenib.
• Haematological malignancies: CML/Ph+ ALL: BCR-ABL TKIs (imatinib, dasatinib, ponatinib). BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) for CLL, MCL, WM. PI3K inhibitors for follicular lymphoma. BCL-2 inhibitor (venetoclax) for CLL and AML (with azacitidine). FLT3 inhibitors (midostaurin, gilteritinib) for FLT3-mutated AML. IDH inhibitors (enasidenib, ivosidenib) for IDH-mutated AML and cholangiocarcinoma.

Mandatory molecular profiling before targeted therapy:

• Comprehensive tumour molecular profiling is the prerequisite — targeted therapy is only effective in tumours harbouring the specific target. Prescribing a targeted agent without biomarker confirmation is inappropriate and may withhold more effective alternatives.
• Tissue NGS: Standard — 300–500 gene panel covers most actionable alterations, TMB, and MSI. Adequate tumour tissue (10–15% cellularity minimum) required.
• Liquid biopsy (ctDNA): Blood test detecting circulating tumour DNA fragments; acceptable when tissue is insufficient or inaccessible; may detect resistance mutations at relapse that re-biopsy cannot (e.g., EGFR T790M resistance mutation — detectable in plasma before osimertinib resistance becomes clinically apparent).
• IHC testing: HER2 amplification (IHC + FISH), PD-L1 expression, ALK fusion protein (IHC D5F3 clone for lung), PTEN expression for PI3K pathway assessment.

Performance status and organ function:

• TKIs: generally well-tolerated; patients with PS 3–4 may still be candidates for highly effective, low-toxicity oral TKIs (e.g., EGFR TKI for EGFR-mutated NSCLC) when anticipated clinical benefit is high
• Hepatic function monitoring required for hepatically metabolised TKIs (most); dose reduction for Child-Pugh B/C liver disease
• Cardiac monitoring for HER2-targeted therapy (LVEF baseline); QTc monitoring for certain TKIs (osimertinib, dasatinib)

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

• Transformative efficacy in biomarker-selected patients: Imatinib for BCR-ABL+ CML: 10-year OS ~85% — a disease previously fatal in <5 years. EGFR-mutated NSCLC (osimertinib): mOS 38 months for stage IV metastatic disease. ALK+ NSCLC (alectinib): mPFS 34 months for stage IV disease. These outcomes vastly exceed what was achievable with chemotherapy in these biomarker-defined populations.
• Manageable, distinct toxicity profile: TKIs and targeted antibodies have toxicity profiles distinct from chemotherapy — typically no myelosuppression (except BTK inhibitors and CDK4/6 inhibitors), no alopecia, no severe nausea. Common TKI-class toxicities (EGFR: rash/diarrhoea; ALK: oedema; BRAF: photosensitivity/squamous cell skin carcinoma risk) are generally manageable grade 1–2 and do not require hospitalisation in most patients.
• Oral convenience: Most small molecule TKIs are oral agents taken once or twice daily at home. This enables patients to maintain quality of life, continue working, and avoid the infusion centre visits required for IV chemotherapy. Medication adherence and access to dose modification guidance are key considerations.
• CNS penetration: 3rd-generation TKIs (osimertinib, lorlatinib, alectinib, selpercatinib) are designed for superior CNS penetration — critical since the brain is a common sanctuary site for lung cancer. These agents achieve significant intracranial response rates (50–90%) in patients with brain metastases, often delaying or replacing whole-brain radiation.
• Antibody-drug conjugate revolution: ADCs combine the tumour-selectivity of monoclonal antibodies with potent cytotoxic payloads (topoisomerase inhibitors, microtubule agents). Trastuzumab deruxtecan (T-DXd) achieves ORR 79% in HER2+ metastatic breast cancer post-pertuzumab (DESTINY-Breast03), significantly superior to T-DM1 (36%). T-DXd also active in HER2-low breast cancer — expanding targetable population from 20% to ~50% of metastatic breast cancer patients.

• Acquired resistance: The principal limitation of targeted therapy. Most patients eventually develop acquired resistance — on-target resistance mutations (e.g., EGFR T790M resistance to 1st/2nd gen TKIs; C797S to osimertinib), off-target bypass pathway activation (MET amplification, KRAS mutation, EMT), or histological transformation (SCLC transformation in EGFR-mutated NSCLC in 5–10%). Serial liquid biopsy ctDNA testing at progression identifies resistance mechanisms and informs next-line treatment selection. Next-generation agents targeting known resistance mechanisms are under development for most major targets.
• EGFR TKI class effects: Acneiform rash/papulopustular eruption (80% with erlotinib/gefitinib; 50% with osimertinib) — reflects on-target EGFR inhibition in keratinocytes; paradoxically associated with better treatment response. Managed with topical clindamycin, doxycycline, emollients. Paronychia (nail fold inflammation) in 20–30%; diarrhoea (20–50%); stomatitis; interstitial lung disease (4% with osimertinib; grade 3–4 in 1%).
• VEGF/VEGFR pathway inhibition: Bevacizumab and TKI anti-VEGF agents (sunitinib, sorafenib, pazopanib): hypertension (20–30%, managed with antihypertensives), proteinuria, wound healing impairment (bevacizumab must be stopped ≥4–6 weeks before elective surgery), arterial thromboembolic events, rare but serious gastrointestinal perforation (<1%), haemorrhage.
• CDK4/6 inhibitor side effects: Palbociclib, ribociclib, abemaciclib cause neutropenia (grade 3–4 in 35–75%) — managed by dose modification and growth factor support; fatigue, nausea, diarrhoea (abemaciclib most). QTc prolongation (ribociclib): ECG monitoring required. Hepatotoxicity (ribociclib): liver function tests monitored monthly for first 6 months.
• HER2 antibody cardiotoxicity: Trastuzumab causes reversible LVEF reduction in 5–10% (distinct mechanism from anthracyclines — reversible on discontinuation). LVEF monitored every 3 months; trastuzumab held for LVEF drop >15% from baseline. Pertuzumab adds minimal additional cardiac risk. T-DXd (trastuzumab deruxtecan): interstitial lung disease in 10–15% of patients — requires early recognition; grade 3–4 ILD in 3%; fatal ILD reported. Dosing guidelines now recommend chest CT before and regular monitoring during treatment.
• PARP inhibitor side effects: Olaparib, talazoparib: anaemia (40–60%, requiring transfusion in 10–20%), neutropenia, nausea, fatigue. Rare myelodysplastic syndrome/AML (0.5–1% at 2 years) — patients should report persistent cytopenias. Niraparib: significant thrombocytopenia in first month requires weekly platelet count monitoring and weight-based starting dose.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Targeted therapy drugs are among the most expensive medications in the world. Generic and biosimilar versions are available in India at a small fraction of Western branded drug costs, making India a major destination for cancer medical tourism:

• India: Indian-manufactured generic TKIs are available at 2–10% of US costs due to India's robust pharmaceutical generic industry and compulsory licensing framework. Examples: Osimertinib (Tagrisso branded USD 18,000/month in USA; Indian generic: USD 400–800/month); Imatinib (branded USD 9,000/month in USA; Indian generic: USD 20–50/month); Gefitinib (branded USD 6,000+/month in USA; Indian generic: USD 30–100/month); Trastuzumab biosimilar (Herceptin branded USD 5,000+/infusion in USA; Indian biosimilar: USD 200–400/infusion). Abiraterone for prostate cancer: USD 9,000–15,000/month in USA; USD 150–300/month generic in India. Full first-year targeted therapy treatment costs: USD 5,000–15,000 in India vs. USD 150,000–300,000+ in USA.
• Thailand: Branded drugs at ~30–40% of US cost; generics limited by stricter IP enforcement than India. USD 3,000–8,000/month for branded TKIs.
• Turkey: Government insurance (SGK) covers approved targeted therapies for Turkish citizens. International private patients: branded drugs at 30–50% of US cost.
• Germany / EU: Statutory health insurance covers NICE/EU-approved targeted therapies. Private sector access: EUR 5,000–15,000/month for novel TKIs.
• United States: Branded targeted therapies: USD 8,000–25,000/month. Annual targeted therapy costs: USD 100,000–300,000. Patient assistance programs (PAP) from manufacturers offer free drugs for eligible low-income patients; co-pay assistance covers commercial insurance co-pays (maximum ~USD 5,000–25,000/year out-of-pocket with co-pay cards).
• United Kingdom (NHS): NICE-approved targeted therapies funded on NHS; Cancer Drugs Fund provides conditional access to newer agents. Some novel agents (trastuzumab deruxtecan for HER2-low breast cancer, sotorasib, adagrasib) required separate NICE evaluation post-FDA approval.

Critical considerations for targeted therapy abroad: (1) molecular profiling must be performed with an accredited laboratory offering comprehensive NGS — results guide drug selection; (2) generic TKIs in India are CDSCO-approved but use separate active pharmaceutical ingredient (API) supply chains from branded originator products — confirm CDSCO approval and GMP manufacturing certification; (3) arrange clear drug supply logistics — ensure adequate drug supply and refill access from India if taking oral TKIs at home; (4) monitoring tests (LFTs, ECG, echocardiogram, CBC) should be performed regularly according to drug-specific monitoring protocols even when back in the home country.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.